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MetforminAims: Deleterious effects of metabolic syndrome (MS) on bone are still controversial. In this
study we evaluated the effects of a fructose-induced MS, and/or an oral treatment with
metformin on the osteogenic potential of bone marrow mesenchymal stromal cells
(MSC), as well as on bone formation and architecture.
Methods: 32 male 8 week-old Wistar rats were assigned to four groups: control (C), control
plus oral metformin (CM), rats receiving 10% fructose in drinking water (FRD), and FRD plus
metformin (FRDM). Samples were collected to measure blood parameters, and to perform
pQCT analysis and static and dynamic histomorphometry. MSC were isolated to determine
their osteogenic potential.
Results: Metformin improved blood parameters in FRDM rats. pQCTand static and dynamic
histomorphometry showed no significant differences in trabecular and cortical bone
parameters among groups. FRD reduced TRAP expression and osteocyte density in trabec-
ular bone and metformin only normalized osteocyte density. FRD decreased the osteogenic
potential of MSC and metformin administration could revert some of these parameters.
Conclusions: FRD-induced MS shows reduction in MSC osteogenic potential, in osteocyte
density and in TRAPactivity. Oralmetformin treatmentwas able to prevent trabecular osteo-
cyte loss and the reduction in extracellular mineralization induced by FRD-induced MS.
 2017 Elsevier B.V. All rights reserved.1. Introduction
Metabolic syndrome (MS) is defined as the group of risk fac-
tors that predispose individuals to the development of type
2 Diabetes and cardiovascular disease [1]. This syndrome
was first described by Reaven in 1988 and initially named ‘‘XSyndrome” [2]. Since then, MS has been subjected to several
revisions with the intention of providing a more suitable def-
inition worldwide. Following this objective, in 2009 a harmo-
nized definition of MS was published [3]. According to this
joint statement, a diagnosis of MS is made when at least 3
of the 5 following risk factors are present: central obesity,Argentina.
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blood pressure, and elevated fasting glucose, with the inclu-
sion of patients taking medication to manage hypertriglyc-
eridemia, low HDL-cholesterol, hypertension and/or
hyperglycemia [3].
The negative effect of Diabetes mellitus (DM) on the skele-
ton and its association with bone fractures is well established
[4]. Patients with type 2 DM and high bone mineral density,
also show an increased rate of osteoporotic bone fractures
[5]. However, less is known about the effects of MS on bone
metabolism. Different reports reveal conflicting results
regarding MS or its individual components, with bonemineral
density and/or fracture risk [6,7].
Western diets are rich in carbohydrates (e.g. fructose and
sucrose) and saturated fats and are associated with MS and
cardiovascular disease. Many MS animal models are based
in the administration of high-carbohydrate or high-fat diets,
to develop one or more of the characteristics of this syndrome
[8]. In particular, high-fructose diets have been successfully
used in animal models to develop MS, displaying classical
clinical and metabolic changes that include: hypertension,
glucose intolerance, hypertriglyceridemia, insulin resistance
and obesity [9–11]. Rats fed a high-fructose diet show a sys-
temic accumulation of advanced glycation end-products
(AGEs) secondarily to the presence of hyperglycemia [12].
Our group and others have shown that AGEs trigger oxidative
stress and inflammatory reactions, both of which are related
to metabolic disorders as well as to impaired bone cell devel-
opment and survival [13,14]. More recently, we have shown
that fructose-induced MS rats display alterations in metaphy-
seal bone microarchitecture and defective bone fracture heal-
ing, possibly as a result of a deviation in the adipogenic/
osteogenic commitment of MSC due to an imbalance in the
Runx2/PPARc ratio [9].
Metformin is one of the most widely used agents for treat-
ment of insulin resistance associated with type 2 DM and MS.
We have shown that metformin also enhances osteoblast pro-
liferation, differentiation and mineralization in the UMR 106
and MC3T3E1 osteoblastic cell lines [15], and induces bone
formation in vivo and ex vivo in normal rats and in partially-
insulin-deficient diabetic rats [16].
Based on these previous observations, we hypothesize that
fructose-induced MS alters osteoblast differentiation and
thus, maintenance of normal bone architecture and that
these effects can be prevented by metformin treatment.Fig. 1 – Schematic representation of the experimental design. C:
FRD: group of rats receiving fructose rich-diet and FRDM: group o2. Materials and methods
2.1. Animals and experimental design
A schematic representation of the experimental design is
shown in Fig. 1. Thirty-two 8 week-old male Wistar rats
(200–220 g) were housed in a temperature-controlled room
at 23 ± 3 C, with average humidity of 30–70%, a 12:12 h light:
dark cycle and continuous access to standard rat laboratory
chow (Asociacio´n de Cooperativas Argentinas, Buenos Aires,
Argentina) and beverage ad libitum. The experiments were
carried out in conformity with the Guidelines on Handling
and Training of Laboratory Animals published by the Univer-
sities Federation for Animal Welfare [17]. All experiments
including animals were approved by the Institutional Ethics
Committee (N 001-05-15).
Animals were randomly divided into two groups of 16 ani-
mals. One of the groups received sterile water ad libitum. The
other group was given a 10% w/v fructose solution (Biopack,
Buenos Aires, Argentina) ad libitum until the end of the study
[9,18,19]. After 14 days of treatment, half the rats from each
group also received 100 mg/kg/day metformin (Quı´mica
Montpellier, Buenos Aires, Argentina) added to their drinking
water for the last 3 weeks of the study. Thus, four experimen-
tal groups of eight animals per group were set: control (C);
control plus metformin (CM); fructose rich diet (FRD); and
fructose rich diet plus metformin (FRDM). Treatment times
were chosen based on previous reports showing that fructose
administration to rats for at least 2 weeks induces metabolic
changes that resemble human MS [10,18,20–25], as well as
bone tissue alterations [9]. The metformin dose of 100 mg/
kg/day that we employed in the in vivo experiments was
within the human therapeutic range as modified by the Guid-
ance of FDA-CDER [26]. In addition, Choi and colleagues [27]
have shown that plasma half-life for oral metformin in rats
is 2 min (versus 5 h in humans), underscoring the need for
significantly higher oral dosing in rats. We have also
demonstrated that oral administration of metformin for
2 weeks induces significant changes in in vivo and in vitro
osteogenic parameters [15,16,28]. Total treatment time was
not prolonged any further to avoid insulin secretion impair-
ment, as explained in Section 4.
Half of the rats from each group received subcutaneous
fluorochromes injections to perform dynamic histomor-
phometry [29]. Briefly, ten days prior to sacrifice rats receivedcontrol group; CM: control plus metformin treatment group;
f rats receiving fructose rich-diet plus metformin treatment.
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Chemical Co., St. Louis, MO), and three days before sacrifice
they received calcein (15 mg/kg body weight; Sigma Chemical
Co., St. Louis, MO).
After 5 weeks of total treatment, rats were weighed and
anaesthetized with ketamine hydrochloride/xylazine. Under
anesthesia, blood samples were obtained from the inferior
vena cava after which animals were euthanized by cervical
dislocation.
Left and right femurs, left tibiae, and first and second lum-
bar vertebrae were dissected, measured using a digital caliper
(Fischer Scientific), and processed as described in each
section.2.2. Blood measurements
Serum was separated from other blood components by cen-
trifugation (3500 rpm, 15 min). Glucose, triglycerides, choles-
terol, insulin, and fructosamine concentrations were
determined. Glucose, triglycerides and cholesterol were mea-
sured by commercial kits (Wiener Laboratories, Rosario,
Argentina) with an automated clinical chemistry analyzer
(Metrolab 2300 plus, Buenos Aires, Argentina). Insulin was
determined by a rat-specific ELISA kit (ALPCO, New Hamp-
shire, USA) and fructosamine was measured by a colorimetric
kit (Biosystems, Barcelona, Spain). Insulin resistancewas esti-
mated with the Homeostasis Model Assessment-Insulin
Resistance (HOMA-IR) index, using the formula ([Glucose
(mg/dL)]  [Insulin (mU/L)]/2430) [30].2.3. pQCT analysis of bone structural parameters
Left femurs and tibiae, and second lumbar vertebrae from
half of the rats per group were stripped of musculature and
placed in 70% ethanol at 4 C until analysis. Bones were
scanned using a Stratec XCT Research M instrument (Norland
Medical Systems, Fort Atkinson, WI) equipped with software
version 6.20. Two scans were performed in the long bones:
the first one at the distal femoral or proximal tibial metaphy-
ses (20% of total bone length), to assess parameters of trabec-
ular bone, and the second one at the midshaft (diaphysis)
(50% of total bone length) to evaluate parameters of cortical
bone [29]. The first scanning sites were determined using
the scout scan and were at the level of the secondary spon-
giosa. Analyzed structural variables were: total bone mineral
content (totBMC), total bonemineral density (totBMD), trabec-
ular bone mineral content (trBMC), and trabecular bone min-
eral density (trBMD) in the metaphysis, and cortical bone
mineral content (cBMC), cortical bone mineral density
(cBMD), cortical thickness, periosteal circumference, and
endocortical circumference in the midshafts.2.4. Structural and static histomorphometric analyses of
distal femoral metaphysis
Distal metaphyses were processed as described in the previ-
ous section. Four lm thick sections were obtained with a
Leica RM 2025 rotatory microtome (Leica Microsystems, Wet-
zlar, Germany). Sections were stained with von Kossa stainand counterstained with Tetrachrome (Sigma–Aldrich, St.
Louis, MO) [31].
To avoid the primary spongiosa and endocortical surfaces,
a region of interest was delimited between 0.5 and 4 mm from
the growth plate, and 0.25 mm from the endocortical
surfaces.
The following parameters were evaluated: trabecular bone
volume (BV/TV, as a percentage of total volume), osteoid
volume (OV/BV, as a percentage of trabecular bone volume),
trabecular number (Tb.N, #/mm), trabecular thickness (Tb.
Th, mm), trabecular separation (Tb.S, mm), osteoblast-
covered surface (Ob.S/BS, as a percentage of trabecular bone
surface), osteoclast-covered surface (Oc.S/BS, as a percentage
of trabecular bone surface), and eroded surface (ES/BS, as the
percentage of trabecular bone surface eroded by osteoclasts).
All these parameters were measured with the Osteomeasure
System (Osteometrics Inc., Atlanta, GA). The terminology
used was based on recommendations by the Histomorphom-
etry Nomenclature Committee of the American Society of
Bone and Mineral Research [32].
2.5. Dynamic histomorphometric analysis of distal
femoral metaphysis
Right femurs of fluorochrome injected rats were stripped of
musculature and fixed in Neutral Buffered Formalin (NBF)
for 24 h. Distal metaphyses were dehydrated in ethanol
solutions, embedded undecalcified in modified methyl
methacrylate and sectioned longitudinally with a Leica RM
2025 rotatory microtome (Leica Microsystems, Wetzlar,
Germany) to obtain 8 lm thick samples as previously
described [29]. Fluorochrome based data were collected using
a Nikon Labophot-2 microscope (Nikon Instruments Inc., Mel-
ville, NY) and the Osteomeasure System (Osteometrics Inc.,
Atlanta, GA). The evaluated dynamic histomorphometric
parameters included: mineralizing surface (MS/BS, calculated
as the sum of the percentage of trabecular bone surface with
double fluorochrome labels plus half of the percentage of tra-
becular bone surfaces with single fluorochrome labels), min-
eral apposition rate (MAR), and bone formation rate (BFR/BS,
calculated by multiplying MS/BS by MAR). Longitudinal bone
growth was calculated as the quotient of the distance
between the second fluorochrome label in the primary spon-
giosa and the limit between hypertrophic and proliferative
chondrocytes in the growth plate, and the time elapsed
between the administration of the second label and sacrifice.
2.6. Structural morphometric analysis in proximal
femoral metaphysis
After sacrifice, the right femora of non-fluorochrome-injected
rats were used for histomorphometric analysis. The bones
were fixed in Neutral Buffered Formalin (NBF) for 72 h and
decalcified by consecutive immersions in 10% EDTA (Biopack,
Buenos Aires, Argentina), pH = 7.0. After decalcification, sam-
ples were dehydrated, embedded in paraffin and sectioned at
five lm using an SM 2000R Leica microtome (Leica Microsys-
tems, Wetzlar, Germany). Sections were stained with H&E or
processed for Tartrate Resistant Acid Phosphatase (TRAP)
detection (Sigma, St. Louis, MO, USA).
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ular bone area, defined as the ratio between trabecular bone
area and total tissue area Tb.Ar/T.Ar [%]; and osteocyte den-
sity defined as the number of osteocytes per square millime-
ter of trabecular bone. Photographs were taken with a
Micrometrics 519CU camera system on an Eclipse E400 Nikon
microscope (Nikon, Tokyo, Japan). Images were analyzed
using the ImageJ Program (http://www.macbiophotonics.ca/
imagej).
2.7. Mesenchymal stromal cells (MSCs) isolation and
incubation
The MSCs were obtained from left femora of 4 rats per group.
Immediately after dissection femoral epiphyses were sec-
tioned and bone marrow cells were collected by flushing with
Dulbecco’s modified essential medium (DMEM) (Invitrogen,
Buenos Aires, Argentina), through the medullary cavity under
sterile conditions [33]. Resulting cell suspensions were seeded
in 25 cm2 culture flasks and incubated in DMEM supple-
mented with 10% fetal bovine serum (FBS) (Natocor, Co´rdoba,
Argentina), and antibiotics (100 UI/mL penicillin, 100 lg/mL
streptomycin) at 37 C in a humidified atmosphere with 5%
CO2 and 95% air. After 24 h, culture medium was changed to
remove non-adherent cells [28]. After this step, medium was
changed twice a week. When cells reached confluence (10–
15 days), the cell monolayer was detached using 0.025% tryp-
sin (GIBCO, Invitrogen, Buenos Aires, Argentina) prepared in
1 mm EDTA and sub-cultured in tissue plates.
2.8. Osteogenic differentiation of MSC
MSCwere seeded in 24-well plates at a density of 5  104 cells/
well and incubated with 10 FBS-DMEM supplemented with
antibiotics at 37 C in a humidified atmosphere with 5 CO2.
After cells reached confluence, they were induced to differen-
tiate into osteoblasts using an osteogenic medium (10 FBS-
DMEM containing 25 lg/mL ascorbic acid and 5 mmol/L
sodium b-glycerolphosphate) for 15 or 21 days [28]. Medium
was changed twice a week. After 2 weeks of osteogenic induc-
tion, the osteoblastic differentiation markers alkaline phos-
phatase (ALP) activity and type 1 collagen production were
determined. Extracellular calcium was measured after
3 weeks of osteogenic induction.Table 1 – Non-fasting serum profiles after 5 weeks of treatment
C CM
Glucose [mg/dL] 170.0 ± 8.3 160.
Insulin [ng/mL] 1.18 ± 0.75 1.09
HOMA-IR index 2.34 ± 0.68 2.08
Triglycerides [mg/dL] 70.0 ± 6.1 58.4
Fructosamine [mmol/L] 130 ± 21 190
Cholesterol [mg/dL] 46.9 ± 1.5 47.9
C: control group; CM: control plus oral metformin group; FRD: group of
receiving FRD plus metformin. HOMA-IR: Homeostasis Model Assessmen
Differences: *p < 0.05 vs C; #p < 0.05 vs CM; †p < 0.05 vs FRD.2.9. Determination of osteoblastic differentiation
parameters
ALP activity and type 1 collagen production was determined
in cultures after 15 days in osteogenic medium. To determine
ALP activity, cell monolayers were washed with phosphate-
buffered saline (PBS) and then lysed with 200 lL of 0.1%
Triton-X100 solution. 100 lL of the lysates were used to eval-
uate ALP activity by hydrolysis of p-nitrophenylphosphate
(p-NPP) to p-nitrophenol (p-NP) at 37 C. p-NP absorbance
was recorded at 405 nm [34]. Protein determination was per-
formed by the Bradford technique using aliquots of the same
lysates [35]. To determine type 1 collagen production cell
monolayers were fixed in Bouin’s solution, stained with Sirius
red dye for 1 h and stained material was then dissolved in
1 mL 0.1 N NaOH. The absorbance of the resulting solution
was recorded at 550 nm [36]. After 21 days of osteogenic dif-
ferentiation, extracellular calcium deposits (mineralization
nodules) were measured using alizarin S red staining [37].
Stained calcium deposits were extracted with 1 mL of 0.1 N
NaOH and the optical density was measured at 548 nm.2.10. Statistical analysis
Results are expressed as the mean ± standard error of the
mean (SEM) except for the pQCT analysis in which results
are expressed as mean ± standard deviation (SD). Differences
between groups were assessed by one-way analysis of vari-
ance (ANOVA) followed by Tukey’s post-test using InStat
Graph Pad 3.0 software (Graph Pad Software, San Diego, CA,
USA). Differences were considered significant when p < 0.05.3. Results
3.1. Body weight and serum profiles
Rats from the different experimental groups had comparable
body weights at the end of the 5-weeks treatment period
(284.0 ± 14.3 g for C, 279.0 ± 14.0 g for CM, 286.7 ± 15.8 g for
FRD, and 289.0 ± 12.2 g for FRDM). Non-fasting serum profiles
of the four experimental groups are shown in Table 1. Glucose
levels were increased in FRD rats and these values were simi-
lar to control values after 2 weeks of metformin administra-
tion. CM group did not show alterations in glucose values,.
FRD FRDM
8 ± 8.6 214.6 ± 12.3*,# 194.7 ± 9.9
± 0.30 5.89 ± 0.98*,# 4.02 ± 3.10
± 0.33 15.00 ± 0.22*,# 9.28 ± 0.82*,#,†
± 4.7 130.1 ± 7.8*,# 115.8 ± 7.3*,#
± 13 218 ± 19* 239 ± 16*
± 0.7 51.1 ± 1.4 45.9 ± 1.9
rats receiving 10% fructose in drinking water; FRDM: group of rats
t-Insulin Resistance index.
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drug. FRD rats also evidenced hyperinsulinemia and hyper-
triglyceridemia. Metformin administration did not change
insulin values in CM compared with C rats. In contrast, insu-
linemia in FRDM group tended to be lower than in FRD rats,
and this tendency was statistically significant when insulin
resistance was estimated with the HOMA-IR index (Table 1).
Furthermore, metformin slightly prevented the elevation of
TG observed in FRD rats. Fructosamine levels were increased
in FRD rats and metformin did not alter these levels (FRDM
group, N.S. vs FRD). No significant differences were observed
in cholesterol levels. These results indicate that the fructose
rich diet induced carbohydrate and lipid metabolism alter-
ations resembling human MS, and that the administration of
metformin for three weeks tended to prevent these changes.3.2. Bone length analysis
Femoral length was comparable among rats of the four exper-
imental groups (32.58 ± 0.19 mm for C, 32.20 ± 0.19 mm for
CM, 32.12 ± 0.21 mm for FRD, and 32.20 ± 0.16 mm for FRDM).
The same result was observed with tibial lengths (37.61
± 0.27 mm for C, 37.03 ± 0.08 mm for CM, 36.99 ± 0.25 mm forTable 2 – pQCT analysis of distal femoral metaphysis and proxi
Distal femoral metaphysis C CM
Total BMC [mg/cm] 11.31 ± 1.46 10
Total BMD [mg/cm3] 660.30 ± 57.74 62
Trabecular BMC [mg/cm] 1.71 ± 0.48 1.4
Trabecular BMD [mg/cm3] 331.10 ± 79.28 28
Proximal tibial metaphysis C CM
Total BMC [mg/cm] 7.29 ± 0.38 7.
Total BMD [mg/cm3] 629.83 ± 21.51 59
Trabecular BMC [mg/cm] 0.71 ± 0.14 0.
Trabecular BMD [mg/cm3] 202.70 ± 37.80 16
C: control group; CM: control plus oral metformin group; FRD: group of
receiving FRD plus metformin. BMC: bone mineral content; BMD: bone m
Table 3 – pQCT analysis of femoral and tibial midshaft to evalu
Femoral midshaft C
Cortical BMC [mg/cm] 8.15 ± 0.24
Cortical BMD [mg/cm3] 1233.85 ± 14.19
Cortical Thickness [mm] 0.76 ± 0.02
Periosteal circumference [mm] 11.05 ± 0.15
Endocortical circumference [mm] 6.26 ± 0.14
Tibial midshaft C
Cortical BMC [mg/cm] 6.22 ± 0.18
Cortical BMD [mg/cm3] 1215.68 ± 10.23
Cortical Thickness [mm] 0.81 ± 0.02
Periosteal circumference [mm] 8.88 ± 0.05
Endocortical circumference [mm] 3.80 ± 0.09
C: control group; CM: control plus oral metformin group; FRD: group of
receiving FRD plus metformin. Results are expressed as the media ± SD.FRD, and 37.50 ± 0.23 mm for FRDM). Similar results were
found for the length of the body of the first lumbar vertebrae
(6.09 ± 0.02 mm for C, 6.51 ± 0.26 mm for CM, 6.43 ± 0.10 mm
for FRD, and 6.30 ± 0.19 mm for FRDM).
3.3. pQCT analysis of trabecular and cortical bone
Trabecular bone parameters assessed in distal femoral meta-
physes and in proximal tibial metaphyses showed no signifi-
cant differences among groups (Table 2). Similar results were
found in the body of the second lumbar vertebrae (data not
shown). In addition, parameters of cortical bone in femoral
and tibial midshaft showed similar values in all experimental
groups (Table 3).
3.4. Structural and static histomorphometric analyses of
distal femoral metaphysis
The evaluation of structural parameters of trabecular bone
present in the distal metaphysis showed similar values for
bone volume (BV/TV; Fig. 2, panel A), number of trabeculae,
trabecular width and trabecular separation among the four
experimental groups (Fig. 2, panels B–D).mal tibial metaphysis to assess trabecular bone status.
FRD FRDM
.34 ± 0.94 10.35 ± 1.07 10.71 ± 0.72
5.25 ± 27.42 645.68 ± 10.35 659.45 ± 18.28
2 ± 0.33 1.47 ± 0.40 1.48 ± 0.22
4.45 ± 48.80 302.83 ± 53.11 303.80 ± 33.93
FRD FRDM
05 ± 0.57 7.26 ± 0.51 7.31 ± 0.40
3.30 ± 12.11 630.33 ± 13.18 616.98 ± 27.38
61 ± 0.08 0.62 ± 0.14 0.60 ± 0.13
9.03 ± 20.44 179.18 ± 24.58 166.35 ± 24.65
rats receiving 10% fructose in drinking water; FRDM: group of rats
ineral density; results are expressed as the media ± SD.
ate cortical bone status.
CM FRD FRDM
8.03 ± 0.34 8.06 ± 0.59 8.12 ± 0.74
1223.33 ± 26.35 1247.03 ± 11.32 1252.03 ± 14.42
0.76 ± 0.01 0.75 ± 0.04 0.76 ± 0.03
11.05 ± 0.31 10.96 ± 0.38 10.93 ± 0.55
6.29 ± 0.31 6.24 ± 0.29 6.18 ± 0.42
CM FRD FRDM
6.14 ± 0.29 6.27 ± 0.57 6.28 ± 0.55
1206.60 ± 8.53 1216.95 ± 12.99 1206.00 ± 11.56
0.80 ± 0.03 0.83 ± 0.07 0.82 ± 0.04
8.89 ± 0.19 8.82 ± 0.34 8.91 ± 0.35
3.88 ± 0.17 3.61 ± 0.19 3.76 ± 0.18
rats receiving 10% fructose in drinking water; FRDM: group of rats
Fig. 2 – Structural histomorphometric analysis of distal femoral metaphysis. C: control group; CM: control plus oral metformin
group; FRD: group of rats receiving 10% fructose in drinking water; FRDM: group of rats receiving FRD plus metformin.
Analysis of trabecular bone structure parameters, including: (A) trabecular bone volume, BV/TV; (B) trabecular number, Tb.N;
(C) trabecular thickness, Tb.Th; and (D) trabecular separation, Tb.S.
Fig. 3 – Static histomorphometric analysis of distal femoral metaphysis. C: control group; CM: control plus oral metformin
group; FRD: group of rats receiving 10% fructose in drinking water; FRDM: group of rats receiving FRD plus metformin.
Analysis of trabecular bone cells parameters including: (A) osteoblast surface, Ob.S; (B) osteoid volume, OV/BV; (C) osteoclast
surface, Oc.S; and (D) eroded surface, ES/BS. Differences: *p < 0.05 vs C, #p < 0.05 vs CM, &p < 0.01 vs CM.
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analysis. FRD and FRDM groups had a trend for a lower,
although not statistically different, osteoblast surface andosteoid volume compared to rats of group C (Fig. 3, panels A
and B). CM rats had higher values for these parameters com-
pared to group C. Osteoclast surface (Oc.S) and eroded surface
Fig. 4 – Dynamic histomorphometric analysis of distal
femoral metaphysis. C: control group; CM: control plus oral
metformin group; FRD: groupof rats receiving 10% fructose in
drinking water; FRDM: group of rats receiving FRD plus
metformin. Fluorochrome-based indices of bone formation
weremeasured in the trabecular bone from thedistal femoral
metaphysis: (A) mineralizing surface, MS/BS; (B) mineral
apposition rate, MAR; and (C) bone formation rate, BFR/BS.
Fig. 5 – Static histomorphometric analysis of proximal
femoral metaphysis. C: control group; CM: control plus oral
metformin group; FRD: group of rats receiving 10% fructose
in drinking water; FRDM: group of rats receiving FRD plus
metformin. Analysis of trabecular bone parameters
including: (A) trabecular bone area, (B) osteocyte density,
and (C) TRAP area in the primary spongiosa. Differences:
*p < 0.05 vs C, †p < 0.05 vs CM, #p < 0.01 vs CM, &p < 0.01 vs
FRD.
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Fig. 6 – Effect of oral metformin on the osteogenic
differentiation potential of MSC from rats with fructose-
induced MS. C: control group; CM: control plus oral
metformin group; FRD: group of rats receiving 10% fructose
in drinking water; FRDM: group of rats receiving FRD plus
metformin. MSC obtained from the femora of the four
experimental groups were cultured in an osteogenic
medium, and then evaluated for alkaline phosphatase (ALP)
activity (A) and type 1 collagen production (B) after 15 days
of differentiation, and formation of extracellular nodules of
mineralization (C) after 21 days of differentiation.
Differences: *p < 0.05 vs C, #p < 0.01 vs C, p < 0.001 vs C,
@p < 0.01 vs CM, &p < 0.001 vs CM.
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experimental groups (Fig. 3, panels C and D).
3.5. Dynamic histomorphometric analysis of distal
femoral metaphysis
Dynamic histomorphometric analysis revealed that MS/BS,
MAR and BFR/BS were not significantly affected by treatments
(Fig. 4, panels A–C). In addition, there were no statistically sig-
nificant differences in femoral longitudinal bone growth
among rats of the different experimental groups (29.45
± 0.74 lm/day for C, 28.91 ± 0.90 lm/day for CM, 27.14
± 2.51 lm/day for FRD, and 28.64 ± 1.24 lm/day for FRDM).3.6. Static histomorphometric analysis of proximal
femoral metaphysis
The analysis of relative trabecular bone area revealed that
although there were no significant differences among groups,
FRD rats tended to show lower values for this parameter
(Fig. 5, panel A). In addition, osteocytic density of trabecular
bone was significantly decreased in FRD rats (86% of C). How-
ever, metformin administration to rats on a fructose rich diet
(FRDM group) restored the values of osteocyte density to
those of the control group (Fig. 5, panel B). Analysis of TRAP
stained bone sections showed that osteoclastic density was
decreased in the primary spongiosa of FRD rats, and that oral
metformin was unable to restore these values to control
levels (Fig. 5, panel C). In rats from group CM, all three param-
eters showed a trend for larger values, although not statisti-
cally different, compared to rats of the C group.
3.7. Osteogenic potential of MSC
After 15 days of osteogenic induction, MSCs derived from FRD
rats expressed lower levels of ALP and produced lower
amounts of type 1 collagen than MSC obtained from C rats
(72% and 62% of C, respectively) (Fig. 6, panels A and B). Sim-
ilarly, after 21 days of osteogenic induction, a significant
decrease in formation of mineralization nodules was
observed in MSC isolated from the FRD group (68% of C)
(Fig. 6, panel C). Metformin administration (FRDM group) did
not modify ALP activity and type 1 collagen production of
MSC, although it completely prevented the fructose-induced
decrease in extracellular mineralization.4. Discussion
Over the past decades, the prevalence of conditions such as
obesity, MS and Diabetes mellitus has increased dramatically.
In particular, MS has become an epidemic due to an increase
in obesity and sedentary lifestyles [38].
Animals fed fructose rich diets (FRD) are widely used as
models of MS, and reflect the effect of environmental fac-
tors on the development of MS. In these models animals
exhibit a metabolic condition that resembles human MS,
showing insulin resistance, dyslipidemia, increased blood
pressure, impaired glucose tolerance and, in some cases,
obesity [10,18,21–25]. We have recently demonstrated that
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ing the osteogenic potential of mesenchymal stem cells
(MSC) [9].4.1. Effects of metformin on glucose and lipid metabolism
in the FRD model of MS
Metformin is an insulin-sensitizing biguanide that is widely
administered to patients with type 2 Diabetes mellitus and/
or MS. It inhibits hepatic glucose production and it may
also improve glucose uptake by peripheral tissues [39]. In
the present study, metformin administration in drinking
water showed slight, although no statistically significant,
beneficial effects on the alterations observed in serum glu-
cose, insulin and triglycerides of FRD rats (Table 1). Never-
theless, metformin induced a significant decrease in the
HOMA-index of fructose-fed rats, suggesting an improve-
ment in the insulin resistance of FDR animals. However,
no changes were observed in fructosamine levels, indicat-
ing that in our experimental conditions metformin admin-
istration does not have a beneficial effect in controlling the
increase in non-enzymatic glycosylation of serum proteins
induced by FRD that has been previously described by
other authors [12,40].
4.2. Effects of metformin on bone tissue in the FRD model
of MS
In our previous studies we demonstrated that the addition of
10% w/v fructose to the drinking water of rats for four weeks
induced deleterious alterations in bone microarchitecture
and in the regeneration of bone lesions [9].
Metformin has been shown to produce beneficial effects
on certain features of the MS (such as ROS increase) that neg-
atively correlate with bone quality [41,42]. Oral administration
of metformin has also been associated with increased osteo-
genesis in vivo and in vitro [15,16]. Hence, this drug appears to
improve bone cellular machinery by acting directly on osteo-
blasts [15,43] or indirectly by improving characteristics that
negatively affect bone. For example, metformin prevents the
formation of reactive oxygen species (ROS) and this could
avoid the alterations caused by oxidative stress on different
tissues and cells, including osteoblasts [44–46].
Bone was evaluated histomorphometrically, measuring
the number and density of trabeculae as well as the status
of cells that contribute to maintain them; and at the level of
mesenchymal stromal cells (MSCs) analyzing their osteogenic
potential. Confirming our previous findings [9], the results of
this study show that the group of rats which received fructose
and metformin (FRDM group) had similar osteocytic density
compared to control rats, indicating that metformin can pre-
vent the alterations in osteocyte density observed in FRD
group. Although we have not evaluated mechanisms of cell
death in this study, the decrease in osteocyte density of FRD
animals could be due to increased apoptosis, an effect that
could be prevented by metformin. We have previously shown
that metformin can prevent the apoptosis induced by AGEs
on cultured osteoblasts [45]. CM rats showed higher values
for these parameters than C rats, although the differenceswere not significantly different (Fig. 5). A reduction in the
osteocyte network could lead to trabecular bone with a
decreased response to mechanotransduction and/or impaired
ability to repair perilacunar microdamage [47,48]. In vivo stud-
ies have shown that metformin improves bonemicroarchitec-
ture in diabetic rats [16,49], although another study showed
that metformin was unable to prevent bone loss in an
ovariectomy model of osteoporosis [50]. Thus, metformin
should not be considered an anti-osteoporotic drug but rather
an insulin-sensitizer that may secondarily improve bone
metabolism.
The pQCTanalysis of trabecular bone in distal femoral and
proximal tibial metaphyses showed no alterations in the FRD
group (Table 2). The groups of rats that received metformin
(CM and FRDM) did not increase BMC and BMD in cancellous
bone when compared with groups that did not receive the
drug (C and FRD respectively). These results are consistent
with histomorphometric data of distal femoral metaphysis
(Fig. 3). The structural parameters (trabecular bone volume,
trabecular number, trabecular thickness, and trabecular sepa-
ration) observed at this anatomic bone location showed sim-
ilar values in the four experimental groups. These data
together suggest that the duration of this study was not suf-
ficiently long enough to induce histologic bone alterations
in vivo. Nevertheless, lack of changes in BMC or BMD does
not imply absence of increased bone fragility and/or bone
alterations. Even though BMD is usually used to estimate frac-
ture risk, it is not always a good predictor because it is related
to bone quantity rather that to its quality. For example,
patients with type 2 Diabetes mellitus show normal or ele-
vated BMD, they also have elevated rates of osteoporotic frac-
tures [51].
In some conditions, such as MS, Diabetes mellitus and
aging, it is frequent to observe formation of advanced glyca-
tion end-products (AGEs) by non-enzymatic glycosylation.
This reaction occurs between amino groups present in pro-
teins, lipids or nucleic acids and reducing sugars or carbonylic
intermediates. Proteins with long half-lives, such as type 1
collagen (which is the principal component of bone tissue
extracellular matrix), are prone to suffer this reaction, partic-
ularly in conditions associated with chronically elevated
plasma glucose levels. This process leads to formation of
pathologic cross-links, which ultimately induce loss of flexi-
bility and elasticity in bone tissue and increased bone fragi-
lity. In addition, excess AGEs alters bone cell homeostasis
via their binding to specific plasma membrane receptors,
leading to decreased osteoblast and osteoclast functions
and eventually decreased bone turnover and bone tissue
quality [12,14].
Osteoblast surface and osteoid volume are two important
parameters of bone formation [49]. The analysis of these
parameters in distal femoral metaphysis showed lower values
for FRD group, although the difference was not statistically
significant (Fig. 3). Metformin administration to FRD rats
(FRDM group) did not improve these parameters, although
CM rats had increased osteoid volume. Osteoid synthesis is
the first step in bone formation, leading to mature bone after
its mineralization. Bone resorption-related parameters
(osteoclast and eroded surfaces) showed no significant differ-
ences among experimental groups (Fig. 3). These results sug-
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not enough to normalize the mild alterations observed in
bone remodeling parameters in rats of the FRD group. Osteo-
blasts and osteoclasts act in a coordinate fashion during bone
remodeling. Remodeling cycles, where a normal osteoclastic
activity is followed by reduced osteoblast activity for longer
periods of time than those observed in this study, could lead
to negative bone balance and promoting skeletal bone loss.
Dynamic histomorphometric parameters of the distal
femur were similar in the four experimental groups (Fig. 4),
showing no differences in the bone formation rate or in lon-
gitudinal bone growth. This is in agreement with the similar-
ities between bone lengths across all experimental groups.
4.3. Effects of metformin on mesenchymal stromal cells
Mesenchymal stromal cells (MSC) are the precursors of all the
cells present in bone tissue, except osteoclasts. Modifications
in the bone marrowmicroenvironment could lead to a shift in
the differentiation potential towards different cell lines. In
MS, the presence of ROS, proinflammatory cytokines, or AGEs
could reduce MSC osteogenic potential and predispose the
cells to other phenotypes. We have previously demonstrated
that fructose induced MS is associated with a deviation in
the adipogenic/osteogenic commitment of MSC, probably by
modulation of the Runx2/PPARgamma ratio, but no differ-
ences in bone marrow adiposity were seen in this condition
when compared with control rats [9].
It has been reported that metformin has direct ex vivo
effects on MSCs, predisposing these cells to differentiate into
the osteoblastic phenotype instead of into the adipocytic lin-
eage [28]. Similar effects have been seen in MSCs isolated
from rats with partial insulin deficiency [16]. This may lead
to a higher number of osteoblasts and therefore, to an
increased bone formation. In the present study although met-
formin treatment of control animals greatly increased the
osteogenic induction of MSC (for all parameters evaluated),
in FRD animals this effect of metformin was less clear cut.
Metformin administration (FRDM group) did not modify ALP
activity or type 1 collagen production in MSC, although it
completely prevented the fructose-induced decrease in extra-
cellular mineralization. It is possible that the incomplete pre-
ventive effects of metformin observed in this study could be
as a result of the relatively short treatment period used in this
study.
4.4. About the election of treatment time period
The insulin resistance present in this model produces hyper-
glycemia. This produces pancreatic b cells hyperstimulation
as a compensatory mechanism to produce higher amounts
of insulin and try to reduce glycemic values (compensatory
hyperglycemia). If this condition was sustained in time, it
could lead to b cell exhaustion with a consequent decrease
in the functionality or amount of these cells and Diabetes
development [52]. This scenario would change the perspec-
tives of this study because we would not be studying a model
with insulin resistance, but another one with partial reduc-
tion in the secretion of this hormone.In conclusion, our model of FRD-induced MS shows a
reduction in MSC osteogenic induction, in osteocyte density
and in TRAP activity. Thus, FRD appears to induce a decrease
in bone remodeling. Although in our experimental conditions
oral treatment with metformin did not improve all bone
structural alterations induced by FRD, it was able to prevent
trabecular osteocyte loss and the decreased extracellular
mineralization induced by FRD on MSCs.
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